At a glance
- Originator AVANT Immunotherapeutics
- Class Anti-inflammatories; Benzofurans; Cyclohexanes
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 05 Jun 2002 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 07 Sep 1998 No-Development-Reported for Inflammation in USA (Unknown route)
- 29 Aug 1996 Preclinical development for Inflammation in USA (Unknown route)